nal-TREX-own
A tiny dose of an opioid-blocker that paradoxically boosts your body's own endorphins and calms inflammation.
Also known as: LDN
FDA approved for: Opioid and alcohol dependence (at full doses of 50mg)
Last reviewed: April 2026
At full doses (50mg), naltrexone blocks opioid receptors. At ultra-low doses (1.5–4.5mg), something paradoxical happens: it briefly blocks endorphin receptors, which causes your body to produce MORE endorphins and enkephalins as a rebound. This boosts your natural pain relief and immune regulation systems.
Tiny capsule taken at bedtime
Frequency
Nightly
Pain Level
○○○ None
Self-Administered
Yes — at home
Typical Range
1.5mg – 4.5mg
Week 1–2
Vivid dreams are common (endorphin system activating). Possible initial sleep disruption.
Month 1
Inflammation reduction begins. Pain may lessen.
Month 3–6
Full anti-inflammatory and immune-modulating benefits.
Overall: Mild
Vivid dreams
Most common effect — indicates endorphin system activation.
Sleep disturbance
Initial insomnia or disrupted sleep. Usually resolves in 1-2 weeks.
Headache
Usually temporary.
• Currently taking opioid medications
• Active liver failure
• Currently taking immunosuppressants (discuss with provider)
• Opioid medications — LDN will block their effects and may cause withdrawal
• Immunosuppressants — may counteract
• Thyroid medication — may need dose adjustment as inflammation improves
Pregnancy: Limited safety data at low doses. Avoid during pregnancy unless directed by provider.
Both modulate immune function. LDN works through endorphin/TLR4 pathways. Thymosin Alpha-1 works directly on T-cells. Different mechanisms, complementary goals.
Open Full Comparison Tool →We don't currently offer this peptide — but we have protocols for similar goals.
Coming Soon →This is a compounded medication prescribed off-label. It has not been FDA-approved for the uses described. All prescribing decisions are made by your independent licensed provider.